ASGCT 2026: Tenaya Therapeutics today presented interim clinical data for its gene therapy for patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 mutations
CEO Faraz Ali walks us through the data, which included six patients, and sets the table for a future update on a gene therapy program for hypertrophic cardiomyopathy that will be announced before the end of the quarter. Coverage brought to you by
13 hours ago
ASGCT 2026: Aurion Biotech is developing an off the shelf cell therapy solution for Corneal endothelial disease, a type of blindness, where only donor transplants are currently available to some
Founder, CSO & CEO Arnaud Lacoste describes the treatment, which is derived from one donor and can treat up to 1,000 patients, and comes in a solution containing a rho-kinase inhibitor. It is currently in a U.S. pivotal study. Coverage brought to you by
14 hours ago
ASGCT 2026: Benitec Biopharma presented a clinical update of its lead DNA-directed RNA interference program targeting Oculopharyngeal Muscular Dystrophy (OPMD)
Executive Chair & CEO Jerel Banks describes how Benitec is programing the body to create its own internal continuous RNAi factory to treat this disease. With this clinical data in hand, Benitec plans to meet with FDA about the design of a pivotal trial. Coverage brought to you by
17 hours ago
.png){kind=logo}
